News Archive
Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.
Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.
Canadian researchers have found that childhood abuse victims who later commit suicide have marked genetic differences in their brains.
Ubichem, a leading provider of chemistry services to the drug development sector, through its Hungarian operation - Ubichem Research - has successfully completed a regulatory inspection and is now approved for the supply of cGMP radiolabelled Active Pharmaceutical Ingredients (APIs).
Focusing HIV drug development on immune cells called macrophages instead of traditionally targeted T cells could bring us closer to eradicating the disease, according to new research from University of Florida and five other institutions.
› Verified 8 days ago